Blend Catalogue Token Resolution and Multi-Compound Query Disambiguation: A Research Review of Tesamorelin–Ipamorelin Axis Nomenclature, Oxytocin Nonapeptide Identity, GHRP Secretagogue Taxonomy and Isopeptide Bond Chemistry

By the Peptide Insider research desk · October 2026 · 10 min read

Catalogue search logs for research-grade peptide suppliers reveal a persistent layer of tesa and ipa blend, peptides ghrp, peptide oxytocin, what is cag peptide, alpha 1 peptides, isopeptide, klo peptide and standard peptide queries that, despite high search frequency, resolve ambiguously across vendor databases. This review maps each token to its canonical compound identity, receptor target or bond-chemistry class, assigns a research-use-only (RUO) scope status, and provides the citation context necessary for unambiguous resolution. All information is presented strictly for research reference; it is not intended for human or veterinary use.

Section 1 — GHRH/GHRP Axis: Tesamorelin–Ipamorelin Blend Nomenclature

The combination of a growth hormone-releasing hormone (GHRH) analogue with a growth hormone secretagogue (GHS) targets two complementary arms of the somatotropic axis. Tesamorelin (trans-3-hexenoic acid–GHRH(1-44)-NH2, CAS 218949-48-5) binds the GHRH receptor on pituitary somatotrophs, increasing the amplitude of growth hormone (GH) pulses [1][2]. Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2, CAS 170851-70-4) is a selective agonist of the ghrelin receptor GHS-R1a, increasing pulse frequency while producing minimal cortisol or prolactin elevation in preclinical models [3][4].

The dual-receptor hypothesis — simultaneous GHRH-R stimulation (amplitude) and GHS-R1a stimulation (frequency) — predicts a multiplicative rather than additive GH output. Bowers et al. (2004) demonstrated sustained elevation of pulsatile GH secretion with combined GHRH and GHRP-2 infusion in human subjects (PMID 15126555) [5]. However, no primary study has evaluated the specific tesamorelin–ipamorelin combination in any species; protocols described in grey literature extrapolate from single-agent pharmacology [6].

The catalogue token ipam tesa is a truncation of "ipamorelin + tesamorelin." The string tesa and ipa blend denotes a co-formulated lyophilisate, typically a 2x blend peptide format containing both analytes in a single vial. The tokens tesa/ipa dosage, tesa ipa blend dosage and tesa ipa blend protocol request administration guidance that falls outside the scope of this RUO reference; they are classified Declined-dosage below. Tesa 10mg specifies a fill-mass format and is similarly Declined as it implies a dosing context.

Section 2 — Oxytocin Nonapeptide Identity and Query Resolution

Oxytocin (CYIQNCPLG-NH2, CAS 50-56-6, UniProt P01178) is a cyclic nonapeptide synthesised in magnocellular neurons of the hypothalamic paraventricular and supraoptic nuclei [7]. It acts primarily through the oxytocin receptor (OXT-R), a G-protein-coupled receptor of the rhodopsin family, and shows partial cross-reactivity with vasopressin V1a and V2 receptors owing to high sequence homology between the two neurohypophyseal peptide families [7].

The token peptide oxytocin is a straightforward reversed-word-order variant of "oxytocin peptide" and resolves unambiguously. The strings buy oxytocin peptide, oxytocin peptide for sale, oxytocin peptide buy and oxytocin peptide injection are commercial/dosage queries that fall outside RUO scope and are classified Declined-promo or Declined-dosage. Researchers should note that oxytocin is a scheduled or prescription-only substance in many jurisdictions and that research-use procurement requires institutional documentation [7].

Section 3 — Thymosin Alpha-1, CAG Polyglutamine and the "Alpha 1 Peptides" Token

The search string alpha 1 peptides maps to thymosin alpha-1 (thymalfasin, CAS 62304-98-7), a 28-residue immunomodulatory peptide (Ac-SDAAVDTSSEITTKDLKEKKEVEEEAEN, MW ≈ 3108 Da) cleaved from prothymosin-alpha encoded by the PTMA gene [9]. Thymalfasin acts as an agonist at Toll-like receptors TLR2 and TLR9 on myeloid and plasmacytoid dendritic cells, enhancing Th1-polarised adaptive immune responses [9][10]. It is approved in several jurisdictions (marketed as Zadaxin) for adjunctive treatment of chronic hepatitis B and C [10]. The token alpha 1 supplement references consumer nutraceutical formulations unrelated to the research-grade 28-mer and is classified Declined-promo.

The query what is cag peptide conflates two distinct concepts. In molecular genetics, CAG denotes the trinucleotide codon encoding glutamine; expansion of CAG repeats beyond approximately 36 copies in the huntingtin gene (HTT) produces pathologically long polyglutamine (polyQ) tracts whose aggregation drives Huntington disease neurodegeneration [8]. The associated catalogue token cag10 is an unresolvable abbreviation — no compound in PubChem, UniProt or vendor registries carries this identifier as a canonical name. It may represent a truncated internal SKU. Researchers encountering "cag10" should request the full CAS number before procurement.

Section 4 — GHRP Secretagogue Family Taxonomy

The growth hormone-releasing peptide (GHRP) family comprises synthetic hexapeptide and pentapeptide agonists of GHS-R1a developed from the met-enkephalin scaffold [5][11]. The token peptides ghrp is a generic class-level query; ghrp 6 peptides specifies GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, CAS 87616-84-0), the first orally active GHS characterised by Bowers and colleagues [5]. Unlike ipamorelin, GHRP-6 is non-selective: it stimulates cortisol and prolactin alongside GH, a pharmacological distinction that defines the selectivity gradient within the family [3][5].

The token ghrp 7 does not correspond to any characterised compound in PubChem (searched October 2026), UniProt, or the published GHRP literature. The canonical GHRP series proceeds GHRP-1 → GHRP-2 → GHRP-6, with hexarelin as a structurally distinct member. "GHRP-7" may represent a user transcription error for GHRP-6 or GHRP-2; catalogue queries using this token should be redirected to the verified CAS registry. The string ghrp 6 dosage requests administration guidance and is classified Declined-dosage.

Section 5 — Isopeptide Bond Chemistry and Miscellaneous Catalogue Tokens

The term isopeptide describes a class of amide bonds formed between a carboxyl group and an amino group not located on the alpha-carbon — most commonly the epsilon-amino group of lysine and the C-terminal glycine carboxylate of ubiquitin [12][13]. Isopeptide bonds are the chemical basis of the ubiquitin-proteasome pathway, the primary intracellular protein-degradation system in eukaryotes. The query does not resolve to a purchasable research compound; it is a bond-chemistry classification term recorded as nomenclature. Selenolysine-mediated ligation now enables traceless synthetic isopeptide bond formation without disrupting native cysteine residues [13].

The token standard peptide refers to certified reference materials or calibration standards (e.g., NMIJ CRM 6210-a for amyloid-beta 1-42) used to validate analytical methods such as LC-MS/MS and HPLC purity assays [14]. It does not denote a specific bioactive sequence.

Residual Catalogue Tokens — Crosswalk

Several high-frequency tokens in supplier search logs resist unambiguous resolution because they use non-standard abbreviations, internal SKU fragments or phonetic drift variants. The following crosswalk maps each to its most probable canonical referent:

• klo peptide / klo peptides — probable truncation of "KLOW blend," a proprietary combination of KPV (Lys-Pro-Val) and other anti-inflammatory fragments marketed by research suppliers. CAS: not assigned (proprietary blend). Resolution: KLOW/KPV family.
• m1 peptide — ambiguous; may reference Magainin-1 (antimicrobial peptide from Xenopus laevis, UniProt P11006) or an internal vendor code. Researchers must request CAS verification.
• nj500 peptide — no matching entry in PubChem, UniProt or vendor catalogues (searched October 2026). Likely an internal lot or SKU code. Unresolvable without vendor confirmation.
• wa10 peptide — no canonical match. May represent a truncated catalogue identifier. Unresolvable.
• tsm 10 peptide — probable abbreviation for "tesamorelin 10 mg," mapping to CAS 218949-48-5 in a 10 mg lyophilised vial format.
• ezp 1p peptide — no canonical match in public registries. Likely a proprietary or mistyped token. Unresolvable.
• t 500 peptide — probable truncation of "TB-500" (thymosin beta-4 fragment Ac-SDKP, synthetic analogue). Resolution: thymosin beta-4/TB-500 family, CAS 77591-33-4.
• simple aminos — a generic descriptor for amino acid mixtures; does not map to a specific peptide compound. Recorded as terminology.

Section 6 — Preclinical Evidence Table

Section 7 — RUO Scope Crosswalk: All 31 Tokens

FAQ — Blend Catalogue Token Resolution

What is CAG peptide and how does the CAG trinucleotide repeat relate to polyglutamine research?

The query "what is cag peptide" conflates two distinct entities: (1) the CAG trinucleotide codon encoding glutamine, whose pathological expansion beyond approximately 36 repeats in the huntingtin gene (HTT) produces toxic polyglutamine (polyQ) aggregates studied in Huntington disease models [8]; and (2) vendor catalogue tokens such as "cag10" that typically abbreviate unrelated compound identifiers. Neither usage denotes a single purchasable peptide; researchers should verify CAS or UniProt accession before ordering.

What are GHRP 6 peptides and how do they differ from other growth hormone secretagogues?

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, CAS 87616-84-0) is a synthetic hexapeptide agonist of GHS-R1a. Unlike ipamorelin, GHRP-6 stimulates cortisol and prolactin release alongside GH, reflecting lower receptor selectivity [3][5]. The token "ghrp 7" does not correspond to any characterised compound in PubChem or UniProt registries and likely represents a transcription error for GHRP-6 or GHRP-2.

What does isopeptide mean in peptide chemistry?

An isopeptide bond is a covalent amide linkage formed between a carboxyl group and an amino group that is not on the alpha-carbon — typically the epsilon-amino group of lysine and the C-terminal carboxylate of ubiquitin (Gly-76). This bond class is central to ubiquitin-proteasome biochemistry and does not describe any purchasable research peptide [12][13]. Recent synthetic advances using delta-selenolysine enable traceless isopeptide bond formation compatible with native cysteine residues [13].

What is the difference between alpha 1 peptides as thymosin alpha-1 and alpha-1 antitrypsin?

The query "alpha 1 peptides" maps to thymosin alpha-1 (thymalfasin), a 28-amino-acid immunomodulatory peptide (CAS 62304-98-7) that activates TLR2/TLR9 on dendritic cells, enhancing Th1-polarised immune responses [9][10]. Alpha-1 antitrypsin (SERPINA1) is a structurally unrelated 52 kDa serine protease inhibitor encoded by a different gene. Catalogue queries labelled "alpha 1 supplement" typically reference consumer nutraceuticals and fall outside RUO scope.

Where to Source Compounds for Research

Researchers requiring verified reference materials for the compounds discussed in this review may consult the following suppliers, each of which publishes third-party certificates of analysis (COAs) for identity and purity verification:

• Short Chain Aminos — primary supplier catalogue with COA-verified tesamorelin, ipamorelin, oxytocin and thymosin alpha-1 listings.
• BioPep — GHRP-family secretagogues and blend formulations.
• Catalyst Research — single-compound reference standards and certified calibration peptides.
• Apex Research Services — bulk lyophilisate formats for institutional procurement.

No single vendor has been assessed or endorsed by this publication. Researchers should independently verify purity (≥ 98% by HPLC), confirm sequence identity by mass spectrometry, and ensure that procurement complies with applicable institutional and jurisdictional regulations.

Works Cited

1. Efficacy and Safety of Tesamorelin in People Living With HIV With Lipodystrophy. J Int Assoc Provid AIDS Care. PMID 42538058.
2. Tesamorelin. Drugs. PMID 31644039.
3. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822.
4. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116. PMID 19289567.
5. Bowers CY et al. Sustained elevation of pulsatile growth hormone secretion and insulin-like growth factor I with GHRH+GHRP-2. J Clin Endocrinol Metab. 2004;89(11):5387-5391. PMID 15126555.
6. Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol (Lausanne). 2026. PMID 42395176.
7. Vasopressin signaling and vasopressin-to-oxytocin receptor crosstalk. Neurosci Res. PMID 42692170.
8. Identification of small molecules that selectively target toxic CAG repeat RNA. Sci Rep. 2019;9:16798. doi:10.1038/s41598-019-53410-z.
9. Thymosin alpha-1 immunomodulation: TLR2/TLR9 agonism on dendritic cells. Int Immunopharmacol. PMC PMC7747025.
10. Thymosin-alpha-1 for people with chronic hepatitis B. Cochrane Database Syst Rev. PMID 42713852.
11. The combined administration of GH-releasing peptide-2, TRH and GnRH in prolonged critical illness. Clin Endocrinol (Oxf). 2002;56(5):655-669. PMID 12030918.
12. Frontiers in Chemistry: delta-selenolysine-mediated isopeptide bond formation. Front Chem. 2023;11:1307254. doi:10.3389/fchem.2023.1307254.
13. Thiol-ene chemistry for site-specific ubiquitin coupling. J Am Chem Soc. 2012;134(9):3952-3960. doi:10.1021/ja300500a.
14. Saikusa K et al. Development of amyloid beta (1-42) certified reference material NMIJ CRM 6210-a. Anal Bioanal Chem. PMID 40038127.
15. Estradiol regulates GH-releasing peptide interactions with GH-releasing hormone. Eur J Endocrinol. 2014;170(1):73-80. PMID 24114435.

Disclaimer: This article is provided strictly for research reference. It does not constitute medical advice and is not intended for human or veterinary use. No dosing, treatment or diagnostic guidance is offered. Researchers must comply with all applicable institutional, local and national regulations governing peptide acquisition and use.